摘要
目的评估补肾强督方治疗强直性脊柱炎肾虚督寒血瘀证的疗效和安全性。方法采用对照研究方法,选择强直性脊柱炎肾虚督寒血瘀证患者,分为补肾强督方治疗组和尪痹冲剂加白芍总苷对照组,观察两组患者临床症状、证候积分、体征、实验室检查的变化;计算两组显效率、有效率和总有效率,并观察药物的副作用;探讨补肾强督方的作用机理。结果两组患者治疗前后全身疼痛、脊柱疼痛、夜间疼痛、晨僵时间、畏寒喜暖、乏力和血瘀证积分均有明显下降;两组患者指地距、胸廓活动度、schober试验、脊柱活动度和4字试验治疗前后均有明显改善;两组患者血沉(ESR)、C反应蛋白(CRP)、外周血单核细胞计数、血小板计数、IgA和IgG治疗前后均有明显改善;补肾强督方治疗AS显效率为30%,,有效率为56.67%,总有效率为86.67%。结论补肾强督方治疗AS,具有明显的抗炎和活血化瘀作用以及一定的免疫调节作用,总有效率高,且安全无明显毒副作用。
Objective To evaluate the curative effect and safety of Bushenqiangdu Formula on ankylosing spondylitis (AS, TCM syndrome of kidney-deficiency, Du-cold and blood-stasis ). Methods The patients with ankylosing spondylitis (TCM syndrome of kidney-deficiency, Du-cold and blood-stasis) were divided into the treatment group treated with Bushenqiangdu Formula and the control group treated with Wangbi Granules combined with total glucosides of white peony. The changes of symptoms, TCM syndrome scores, signs and. indexes of laboratory examination in two groups were observed. The effectual rate, effective rate and total effective rate were calculated in two groups. The side effects were observed and the mechanism of Bushenqiangdu Formula was discussed. Results After the treatment the symptoms of the patients in two groups were relieved and the integral of blood-stasis syndrome were obviously induced. The outcomes oflaboratory examination in two grouPs were improved remarkably. The indexes of ESR, CRP, monocytes count of peripheral blood, platelet count, IgA and IgG were all improved. The effectual rate of Bushenqiangdu Formula on AS was 30 %, effective rate, 56.67 % and total effective rate, 86.67 %. Conclusion Bushenqiangdu Formula has the effects of anti-inflammation, activating blood circulation to remove stasis, and immunoregulation with a higher total effective rate, safety and without side effects.
出处
《北京中医药大学学报》
CAS
CSCD
北大核心
2007年第12期857-860,共4页
Journal of Beijing University of Traditional Chinese Medicine
关键词
强直性脊柱炎
肾虚督寒血瘀证
补肾强督方
临床研究
ankylosing spondylitis
syndrome of kidney-deficiency, Du-cold and blood-stasis
Bushenqiangdu Formula
clinical study